ASCO GU 2025: Optimizing Treatment Selection and Clinical Decision-Making in Advanced RCC - Episode 6
Navigating RCC Progression: Optimizing Treatment Sequence After the First Line
Experts discuss emerging patterns of progression with current frontline regimens for advanced renal cell carcinoma (RCC), differences between immunotherapy (IO)/IO and IO/tyrosine kinase inhibitor (TKI) combinations, and how these progression patterns impact prognosis and subsequent therapy selection, considering whether the patient received IO/IO or IO/TKI in the first line and the clinical factors influencing later-line treatment decisions.
Video Player is loading.
Video content above is prompted by the following:
- In your experience, what patterns of progression are emerging with current frontline regimens for advanced RCC, and are there notable differences between IO/IO and IO/TKI combinations? How do these progression patterns—such as common sites of progression or timing—impact prognosis and influence your choice of subsequent therapy?
- When a patient progresses on frontline therapy, how do you approach treatment selection in the later-line setting?
- Does your choice differ based on whether the patient received IO-IO or IO-TKI in the first line? What clinical and disease-specific factors most influence your decision?